A subsequent retrospective study in the United States of 1,221,218 drug-naïve patients with T2D with or without obesity/overweight had a decreased risk of developing colorectal cancer (HR 0.75; 95%CI: 0.58-0.97) with GLP-1R agonists compared to non-insulin T2D medications and insulin (HR 0.56; 95%CI: 0.44-0.72) over a 15-year follow-up period[10]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.